Syon Capital LLC bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,682 shares of the company's stock, valued at approximately $276,000.
Other hedge funds also recently bought and sold shares of the company. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $28,913,000. Raymond James Financial Inc. bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at $10,611,000. Marshall Wace LLP grew its position in Mirum Pharmaceuticals by 641.6% in the fourth quarter. Marshall Wace LLP now owns 175,913 shares of the company's stock valued at $7,274,000 after purchasing an additional 152,191 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Mirum Pharmaceuticals by 10.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company's stock valued at $58,831,000 after purchasing an additional 138,623 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Mirum Pharmaceuticals by 162.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company's stock valued at $7,317,000 after purchasing an additional 109,585 shares in the last quarter.
Mirum Pharmaceuticals Stock Performance
Shares of Mirum Pharmaceuticals stock traded down $0.01 on Thursday, hitting $43.44. The stock had a trading volume of 125,486 shares, compared to its average volume of 519,659. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.83 and a twelve month high of $54.23. The business's 50 day moving average is $43.51 and its two-hundred day moving average is $44.04. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -21.48 and a beta of 1.00.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have recently commented on MIRM shares. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $58.20.
Check Out Our Latest Report on MIRM
Insider Activity
In related news, CEO Christopher Peetz sold 9,102 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.40. The trade was a 7.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Peter Radovich sold 2,627 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the sale, the chief operating officer now owns 26,961 shares of the company's stock, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,557 shares of company stock valued at $4,726,040. 22.87% of the stock is owned by insiders.
Mirum Pharmaceuticals Company Profile
(
Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Recommended Stories
Before you consider Mirum Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.
While Mirum Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
